GAMMA Investing LLC Has $642,000 Position in DexCom, Inc. (NASDAQ:DXCM)

GAMMA Investing LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 47.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,258 shares of the medical device company’s stock after acquiring an additional 2,665 shares during the quarter. GAMMA Investing LLC’s holdings in DexCom were worth $642,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Geode Capital Management LLC increased its holdings in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after purchasing an additional 214,136 shares in the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares during the last quarter. Groupama Asset Managment lifted its position in DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after buying an additional 31,358 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its holdings in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DXCM. Oppenheimer dropped their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. JPMorgan Chase & Co. increased their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Sanford C. Bernstein upped their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Trading Up 3.3 %

NASDAQ DXCM opened at $81.07 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock’s 50-day moving average is $76.12 and its 200-day moving average is $80.54. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $31.67 billion, a P/E ratio of 48.55, a P/E/G ratio of 2.46 and a beta of 1.12.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.